On December 17, the U.S. Food and Drug Administration (FDA) approved rituximab-arrx (Riabni), a biosimilar to rituximab (Rituxan), for the treatment of adult patients with non-Hodgkin lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis (Wegener's granulomatosis), and microscopic polyangiitis. The biosimilar will be made available in the United States in January 2021.
The phase II ZUMA-12 trial found that axicabtagene ciloleucel, an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, is a safe and effective first-line therapy for patients with high-risk large B-cell lymphoma. These results were presented by Sattva S. Neelapu, MD, and colleagues at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition.
For patients with indolent follicular lymphoma, generally take a conservative approach to treatment unless the patient is symptomatic, advised John P. Leonard, MD, Executive Vice-Chair of Weill Department of Medicine at Weill-Cornell Medicine/NewYork-Presbyterian, New York.
Many patients with diffuse large B-cell lymphoma (DLBCL) may be cured by autologous stem cell transplant, but as many as half eventually relapse. New research presented by Reid Merryman, MD, and colleagues at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition suggests that patients whose blood or stem cell samples harbor circulating tumor DNA (ctDNA) may be more likely to experience disease relapse.
In the phase II ZUMA-5 trial, axicabtagene ciloleucel led to responses in 92% of patients with indolent non-Hodgkin lymphoma treated with the cellular immunotherapy. These findings were reported by Caron Jacobson, MD, MMSc, and colleagues at the ASH Annual Meeting & Exposition.